NeoVirTech

Executive Summary

NeoVirTech is a Paris-based biotechnology company founded in 2015, specializing in a proprietary imaging platform called ANCHOR™ that enables real-time visualization and quantification of viral infection and replication in living cells. This technology addresses a critical bottleneck in virology research by providing dynamic, high-content data that traditional endpoint assays cannot capture. The company's platform has broad applications across antiviral drug discovery, gene delivery optimization, oncolytic virotherapy development, and disinfection efficacy testing. By enabling direct observation of viral behavior in live cells, ANCHOR™ offers the potential to significantly accelerate R&D timelines and improve the predictivity of preclinical models. As a private, early-stage company, NeoVirTech is positioned to capitalize on the growing demand for advanced virology tools, particularly in the wake of recent pandemics and increased focus on pandemic preparedness. The platform's versatility suggests it could serve as a key enabling technology for multiple sectors, including pharma, biotech, and academic research. However, the company faces typical early-stage risks including validation requirements, commercialization challenges, and competition from established imaging and assay providers. Its success hinges on securing strategic partnerships, demonstrating platform utility in high-profile collaborations, and attracting follow-on financing to scale operations.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026Strategic Partnership with Major Pharma for Antiviral Screening50% success
• Q2 2026Publication of Validation Data in Peer-Reviewed Journal80% success